P-Y McLaughlin (@AcadianRO) header
P-Y McLaughlin (@AcadianRO) profile picture

Radiation Oncologist in the Radiation Medicine Program @OttawaHospital @uOttawaRad

Ottawa, Ontario
Joined June 2011
Photo by P-Y McLaughlin (@AcadianRO)Photo by P-Y McLaughlin (@AcadianRO)Photo by P-Y McLaughlin (@AcadianRO)Photo by P-Y McLaughlin (@AcadianRO)Photo by P-Y McLaughlin (@AcadianRO)
Long-term disease-free survival and health-related quality of life results of HDR brachytherapy as monotherapy pubmed.ncbi.nlm.nih.gov/3954… Long term outcomes for prospective trial of HDR monotherapy - very reassuring outcomes, despite most patients not being MR-staged at the time
3
10
616
Today at #ASCO26: MSK radiation oncologist Dr. Nancy Lee (@imrtlee) shared long-term results showing that many patients with HPV-positive #oropharyngeal cancer were able to receive lower-dose radiation while maintaining durable outcomes and experiencing fewer side effects.
29
2
74
18,229
ESTRO statement on the Proteus trial. More deaths in the Apa arm in high risk patients who mostly don’t die from prostate cancer 5-10 years out makes one take a step back estro.org/About/Newsroom/New…
85
P-Y McLaughlin retweeted
🚨🚨 ASCO 2026 Final Results Randomized trial resected brain met Brachytherapy vs Post-Op SRS🚨 - Incredible Surg Bed Control with Brachy (↑↑OS as well) - Surg bed recurrence 12% SRS vs 1% GammaTile
6
45
2
104
6,888
P-Y McLaughlin retweeted
Calling all Brachytherapists, 15 year results from ascende RT presented by #scotttyldesley showing continued biochemical PFS, no OS benefit but benefit in prostate cancer specific deaths. @AmericanBrachy @ASTRO_org
17
53
2,202
Excited to share our latest work in Advances in Radiation Oncology! 🚀 We compared outcomes of 5-fraction adaptive MRI-guided RT for newly diagnosed glioblastoma vs. 15- & 30-fraction regimens using propensity score matching. 📄doi.org/10.1016/j.adro.2025.…
4
10
1
48
11,665
P-Y McLaughlin retweeted
What if this was a drug ?🙂 🆕 NEJM | June 2025 🎯 CHALLENGE Trial: Structured exercise after adjuvant chemo in colon cancer 📦 RCT | n=889 | Median FU: 7.9 yrs 🟠 3-yr structured aerobic program vs health ed alone 📈 Primary Endpoint: Disease-Free Survival (DFS) 🔹 HR 0.72 (95% CI: 0.55–0.94), p=0.02 🔹 5-yr DFS: 80.3% vs 73.9% (+6.4%) 🟨 Overall Survival (OS) 🔸 HR 0.63 (95% CI: 0.43–0.94) 🔸 8-yr OS: 90.3% vs 83.2% (+7.1%) 🧠 Other highlights: 🔻 ↓ Liver recurrence: 3.6% vs 6.5% 🔻 ↓ New primary cancers: 5.2% vs 9.7% 🔻 Improved cardiorespiratory fitness, QoL, 6-min walk ⚠️ AEs: ↑ MSK issues (18.5% vs 11.5%), mostly mild No major safety concerns 🤔 What if this was a drug? 📢 “Breakthrough” 💰 $120K/year 📄 Fast-track approval Instead, it’s just structured EXERCISE. 💡 Prescribe it like we would any other adjuvant therapy. Congratulations to Authors and Dr Chris Booth 👏 #CHALLENGEtrial #ASCO25 @csoncol @oncology_bg @ASCO #ASCO25 @OncoAlert
15
131
18
315
60,974
P-Y McLaughlin retweeted
Presented at #ASCO25: A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results: nej.md/4mh5RPL @ASCO
18
354
82
805
220,435
Relatedly, the ceaseless pressure in oncology to omit adjuvant RT for breast cancer in favor of years of toxic endocrine therapy is as much a betrayal of women’s health as the persistence of Halsted mastectomies long after it was clear they are harmful
Only radiation oncologists could wield a therapy as powerful, safe, and effective as SBRT and pre-emptively apologize for offering it
1
8
32
2,746
P-Y McLaughlin retweeted
Our article on long-term outcomes of the 44/20 and 20/0 randomized trials involving prostate brachytherapy has been published in Practical Radiation Oncology! authors.elsevier.com/a/1k5Jd… @AmericanBrachy
2
2
227
A vaccine has essentially eliminated a dreadful form of cancer. Extraordinary.
729
17,838
263
180,632
8,249,737
When the #radonc contours only the PTV
10
23
2
137
9,527
Wonderful results - can't wait to see more details. BUT- when/why do we endorse PFS as the valid primary endpoint in drug trials in the definitive treatment, but insist on OS for some Ph3 RT trials in metastatic cancer? As we often argued to many protocol review committees, RT is a form of local therapy and is meant for improving local control. Therefore PFS should be a valid endpoint in some situations if accompanied by other meaningful patient-centered measures (PRO/QOL etc.). @JYangMDPhD @seanmmcbride @VPrasadMDMPH @PercyLeeMD @DrPOGaudreau @DrewMoghanaki @IyengarPuneeth @Dr_AliHosni @DrLesterColl @DavidSherMD @jamesbyu @QuynhNguyenMD @Josh_Waka @xrtGenomics FDA approves osimertinib with chemotherapy for EGFR-mutated non-small cell lung cancer fda.gov/drugs/resources-info…
4
11
1
52
30,614
Excellent editorial !! Yes, excluding some therapy whenever it is not needed is necessary.Doesn't matter which modality it is.But the evidence should be strong enough.Not to forget the fact that trial setting is not = real world setting always.
Our editorial on radiation omission trials is out in @JCOOP_ASCO. We analyzed 3 RT omission studies (PROSPECT rectal, PRIME II breast, EuroNet-PHL-C1 peds HL) & described separate methodologic considerations for each trial. @whallradonc, Chris Booth ascopubs.org/doi/10.1200/OP.…
1
2
1
1,103
FINALLY - what I have been looking forward to prove for 20 years: the detection performance of DRE for PCa is so weak that we can forego this exam. Hope the guidelines take this evidence to stop recommending DRE for PCa screening/early detection. sciencedirect.com/science/ar…
20
258
39
797
471,742
Advocates speak out about radiation therapist shortage in New Brunswick atlantic.ctvnews.ca/mobile/a…
1
273
Our inaugural paper, our manifesto is now out in @TheLancetOncol . This paper describes our mission, vision, and guiding principles. We also now invite you all to join our movement- our website is now live. thelancet.com/journals/lanon…
16
149
50
370
296,290